ClinicalTrials.gg
SuspendedNCT07197840CHALLENGERUpdated Oct 28, 2026

The CHALLENGER Registry

An observational study in Chronic Subdural Hematoma, sponsored by Icahn School of Medicine at Mount Sinai. Suspended at 3 sites in United States. Open to participants aged 18 Years to 98 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

How we know

Why this study was suspended
FDA request pause in study and an IDE application to be submitted
Updated Oct 28, 2026Now Suspended2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 98 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.

Started
2025
with 3 others
Observational
7 of 22
5 open now
Registered
15th of 22
by date
Lead sponsor
2 of 22
Icahn School of Medicine at Mount Sinai

Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is one of 4 that started in 2025, is one of 7 observational ones, and was the 15th registered.

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 98 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hematoma, Subdural, Chronic with a site in United States, or all of them as a file.
02

Study summary

The study is a multi-center prospective, single-arm, post-market study evaluating the efficacy and radiologic and functional outcomes associated use of the Numen SILK coils for Middle Meningeal Artery (MMA) embolization following Chronic Subdural Hematoma (cSDH) compared to surgical evacuation or medical management alone.

Chronic subdural hematoma is a collection of blood between the dural mater and the brain. It typically develops over time in older adults or people on anticoagulant medication. Blood slowly accumulates over time and often becomes encapsulated by a fibrous membrane over weeks or months, which can lead to the gradual development of symptoms. Middle Meningeal Artery embolization (MMAE) through coiling provides a minimally invasive option for cSDH treatment and prevention of reaccumulation and recurrence.

Read the detailed description

The NumenFR detachment system is a sterile, handheld, single-patient use device designed for use with the Numen SILK coil embolization system and is operated by two pre-loaded batteries. The analysis of the Numen SILK coil embolization system will occur prospectively if it is determined the patient meets the enrollment criteria. All patients enrolled in the study will receive supportive and medical treatment by choice of the treating physician and in accordance with standard of care. Such treatment includes but is not limited to: neurointensive care, neuromonitoring, and surgical and medical management of cSDH.

03

Conditions studied

  • Chronic Subdural Hematoma
04

Who can participate

Ages eligible
18 Years to 98 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patient population for this study will be comprised of up to 100 patients with chronic subdural hematoma (cSDH).

Eligibility criteria

  • Age 18-98 years inclusively
  • Per CT of the head, (one of the following):

    • Unilateral convexity cSDH measuring at least 10 mm in thickness OR
    • Bilateral cSDH if only one side is considered for treatment and the contralateral side is asymptomatic and \< 5 mm in thickness.
  • cSDH at least 2/3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying cSDH
  • Qualifying baseline head CT performed within the 14 days prior to treatment
  • Patient or legally authorized representative agrees to be participated in the study and provides written and Health Insurance Portability and Accountability Act (HIPAA) authorization

Exclusion Criteria:

  • Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor
  • Bilateral cSDH with unknown origin of symptoms
  • Participants who underwent prior embolization of either MMA
  • Tentorial or interhemispheric SDH
  • mRS >4
  • On tranexamic acid
  • Intractable coagulation dysfunction or abnormal count and function (pre-operative [INR] > 1.5 and/or platelet count \< 80109/L)
  • Anatomical variations that may affect the safety of MMA embolization (e.g., prominent middle MMA ophthalmic artery anastomosis)
  • Known to angiography
  • Known intolerance to occlusion procedures
  • Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or coil embolization
  • Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization.
  • Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial/capillary/venous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization.
  • Patient has a known active systemic infection or sepsis
  • Patient is pregnant, planning to become pregnant, or lactating
  • of less than 6 months due to comorbid terminal conditions
  • Concurrent participation in another research protocol for investigation of an experimental therapy
  • Known or suspected to not be able to comply with the study protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
180 Days
Patient registry
Yes

Groups and cohorts

  • Numen SILK

    Patients treated with the Numen SILK coil embolization system

    Device: Numen SILK coil embolization system

Interventions

  • DeviceNumen SILK coil embolization system

    The Numen SILK coil embolization system is designed to be used in conjunction with the NumenFR detachment system. It consists of two main parts: • Introducer Sheath: The purpose of this sheath is to facilitate the introduction of the coil into the microcatheter. • Coil System: Composed of the pusher and coil implant. The coil is a permanent implant intended to occlude blood flow in vascular abnormalities. The pusher is used to deliver the coil implant to the target lesion. The NumenFR detachment system is a sterile, handheld, single-patient use device designed for use with the Numen SILK coil embolization system and is operated by two pre-loaded batteries

06

What researchers measure

Primary outcomes

  1. Proportion of patients that need rescue surgery or die within 180 days of MMA coil embolization

    The proportion of patients centrally deemed to need rescue surgery or die within 180 days of MMA coil embolization

    Time frame: 180 days

Secondary outcomes

  1. Recurrent or residual chronic subdural hematoma measuring greater than 10 mm in thickness

    Recurrent or residual chronic subdural hematoma at 180 days measuring greater than 10 mm in thickness

    Time frame: 180 days

  2. Number of patients requiring reoperation or surgical rescue within

    Number of patients requiring reoperation or surgical rescue within 180 days

    Time frame: 180 days

  3. Worsening of or death from neurological causes within 180 days

    Worsening of or death from neurological causes within 180 days

    Time frame: 180 days

  4. Major disabling stroke from neurological causes within 180 days

    Major disabling stroke from neurological causes within 180 days

    Time frame: 180 days

  5. Rate of serious adverse events from neurological causes within 180 days

    Rate of serious adverse events from neurological causes within 180 days

    Time frame: 180 days

  6. Change in hematoma thickness

    Change in hematoma thickness from baseline to the repeat scan at 90 days and from baseline to the repeat scan at 180 days

    Time frame: Baseline, at 90 days and at 180 days

  7. Modified Rankin Scale (mRS) score at 90 days and at 180 days

    Modified Rankin Scale score at 6 months will be collected to determine patient functional outcomes at 6 months. The scale runs from 0-6, running from perfect health without symptoms to death: * 0 - No symptoms. * 1 - No significant disability. Able to carry out all usual activities, despite some symptoms. * 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. * 3 - Moderate disability. Requires some help, but able to walk unassisted. * 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. * 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. * 6 - Dead.

    Time frame: at 90 days and at 180 days

  8. Number of target MMA injuries related to study device

    The number of injuries to the target middle meningeal artery (MMA) that are determined to be related to the study device, as identified through adverse event reporting during the study period.

    Time frame: 180 days

07

Study locations

3 sites
  • John Muir Health
    Walnut Creek, California 94598, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Northwell Health
    New York, New York 10075, United States
08

References and documents

Individual participant data

Plan to share: No — Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. The intention will be to publish together between the principal investigator and the sponsor. Following publication, Mount Sinai will archive and store all associated data on its cloud-based system.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Sep 29, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended FDA request pause in study and an IDE application to be submitted
changed Oct 28, 2026
Sites
2 sites added
Show 2 added (2 United States)
  • John Muir Health · Walnut Creek, United States
  • Northwell Health · New York, United States
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Suspended
    Why stopped FDA request pause in study and an IDE application to be submitted
    2 sites added
    Show 2 added (2 United States)
    • John Muir Health · Walnut Creek, United States
    • Northwell Health · New York, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07197840
Responsible party
Shahram Majidi (Associate Professor of Neurosurgery, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Sep 29, 2025
Start date
Nov 20, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Shahram Majidi
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion